January 5, 2010
Clinical Trial Announcement
Study: Proton Radiation Therapy in Treating Patients With Prostate Cancer
Status: Recruiting
Sponsor: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Link: Click Here
December 30, 2009
Clinical Trial Announcement
Study: Preoperative Radiation Therapy for High Risk Prostate Cancer
Status: Recruiting
Sponsor: Duke University
ClinicalTrials.gov Link: Click Here
December 24, 2009
Clinical Trial Announcement
Study: Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
Status: Recruiting
Sponsor: University of Florida
ClinicalTrials.gov Link: Click Here
December 17, 2009
Clinical Trial Announcement
Study: Ketoconazole and Dexamethasone in Prostate Cancer (Keto/Dex)
Status: Recruiting
Sponsor: University of California, San Francisco
ClinicalTrials.gov Link: Click Here
December 11, 2009
Industry News
December 7, 2009
Clinical Trial Announcement
Study: MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate
Status: Recruiting
Sponsor: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Link: Click Here
December 3, 2009
Clinical Trial Announcement
Study: Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
Status: Recruiting
Sponsor: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Link: Click Here
November 30, 2009
Clinical Trial Announcement
Study: Abiraterone Acetate, Prednisone, and Leuprolide Acetate Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer
Status: NOT YET Recruiting
Sponsor: Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Link: Click Here
November 24, 2009
Clinical Trial Announcement
Study: Hormone Therapy With or Without Bevacizumab in Treating Patients With Recurrent Prostate Cancer
Status: NOT YET Recruiting
Sponsor: Cancer Institute of New Jersey
ClinicalTrials.gov Link: Click Here
November 19, 2009
Clinical Trial Announcement
Study: Abiraterone Acetate Plus Prednisone Drug-Drug Interaction With Dextromethorphan and Theophylline Treating Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting
Sponsor: Cougar Biotechnology
ClinicalTrials.gov Link: Click Here
November 16, 2009
Industry News
Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
November 4, 2009
Industry News
Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer Treatment and Predicting Disease Free Survival
November 3, 2009
Prostate Cancer Clinical Trial Results
Shorter Radiation Course as Effective as Standard Therapy For Prostate Cancer Recurrence
Prostate Cancer Clinical Trial Results
Shorter Radiation Course Stops Cancer Growth in High-Risk Prostate Cancer Patients
November 2, 2009
Industry News
Dendreon Completes Submission of Biologics License Application for PROVENGE
Prostate Cancer Clinical Trial Results
Adding Proton Therapy ‘Boost’ to X-Ray Radiation Therapy Reduces Prostate Cancer Recurrences
Prostate Cancer Clinical Trial Results
Short-Term Hormone Therapy Added to Radiation Increases Survival for Medium-Risk, But Not Low-Risk, Prostate Cancer Patients
October 6, 2009
Industry News
FDA Grants Additional Fast Track Designation for OGX-011 in Combination with First Line Chemotherapy
BOTHELL, WA, and VANCOUVER, Oct. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment. OncoGenex had previously received Fast Track Designation for second-line docetaxel treatment with OGX-011 in combination with docetaxel for treatment of progressive metastatic prostate cancer following docetaxel.
October 1, 2009
Prostate Cancer Clinical Trial Results
Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery
Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery. The study demonstrated that erectile function was preserved in 81 percent of patients at a median follow-up of two years. Published rates of erectile function preservation at two years for other commonly used prostate cancer treatments, such as open surgery and conventional radiation therapy, range from 50-70 percent.
September 29, 2009
Prostate Cancer Clinical Trial Announcement
Study: A Study of the Safety and Efficacy of Single-agent CNTO 888 (an Anti CC-Chemokine Ligand 2 [CCL2]) in Patients With Metastatic Prostate Cancer
Brief Description:Â The purpose of this study is to determine the safety and effectiveness of the study drug CNTO 888 in patients with metastatic castrate-resistant prostate cancer.
Status: Recruiting
Sponsor: Centocor, Inc.
ClinicalTrials.gov Link: Click Here
September 9, 2009
Prostate Cancer Clinical Trial Announcement
Study: Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)
Brief Description:Â This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy
Status: Recruiting
Sponsor: Medivation, Inc.
ClinicalTrials.gov Link: Click Here
September 1, 2009
Prostate Cancer Clinical Trial Announcement
Study: Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer
Brief Description: The purpose of this trial is to evaluate a short course of very focused (stereotactic) external beam radiation therapy for the treatment of early stage prostate cancer. The investigators will gather scientific information about the tolerance and side effects this type of radiation. The investigators will then compare these results with those of standard 8 week course of external beam radiation therapy to see if this study treatment is equally or more effective in treating prostate cancer.
Status: Recruiting
Sponsor: San Diego Radiosurgery
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
Study: Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy (PR06)
Brief Description: Patients are being asked to take part in this study because they had prostate cancer that was treated surgically and it has been determined that they might have a greater risk of their prostate cancer returning or their prostate cancer has already returned. The purpose of this study is to see what effects, good and/or bad, image guided proton based radiation therapy, and/or conventional radiation therapy and hormonal therapy (if applicable), has on the patient’s prostate cancer that has already returned or the risk of their prostate cancer returning. With the patient’s consent, this study will also look at their prostate cancer tissue that was removed during their surgery for information that may help to treat prostate cancer in the future.
Status: Recruiting
Sponsor: University of Florida
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Results
August 27, 2009
Industry News
August 24, 2009
Advocacy/Support
August 20, 2009
Advocacy/Support
August 4, 2009
Industry News
July 29, 2009
Prostate Cancer Clinical Trial Announcement
Study:Â Â Active Surveillance for Cancer of the Prostate (ASCaP)
Brief Description: Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.
Status: Recruiting
Sponsor: University of California, Los Angeles
ClinicalTrials.gov Link: Click Here
July 28, 2009
Industry News
July 24, 2009
Prostate Cancer Clinical Trial Announcement
Study:Â Â Study Using WST11 In Patients With Localized Prostate Cancer (PCM202)
Brief Description: The aim of this study is to determine the optimal treatment conditions (WST11 dose and light energy dose) to achieve ablation in one lobe of the prostate and to evaluate the safety and quality of life of WST11 medicated Vascular-Targeted Photodynamic therapy (VTP) in men with localized prostate cancer.
Status: Recruiting
Sponsor: Steba Biotech S.A.
ClinicalTrials.gov Link: Click Here
July 22, 2009
Prostate Cancer Clinical Trial Announcement
Study:Â Â Pazopanib as Second Line Therapy in Patients With Prostate Cancer Refractory to Total Androgen Blockade
Status: Recruiting
Sponsor: Illinois CancerCare, P.C.
ClinicalTrials.gov Link: Click Here
June 19, 2009
Advocacy/Support
Soccer Hall of Famer Marcelo Balboa Encourages Men to ‘Team Up Against Prostate Cancer’
June 17, 2009
Prostate Cancer Clinical Trial Announcement
Study:Â Â Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer
Status: Recruiting
Sponsor: Beth Israel Medical Center
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
Study: Neoadjuvant Abiraterone Acetate plus leuprolide acetate in men with localized high risk prostate cancer
Status: Not yet recruiting*
Anticipated start or recruitment:Â July 2009
Sponsor: Cougar Biotechnology
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the “subscribe” link at the top of the page.
June 11, 2009
Prostate Cancer Clinical Trial Announcement
Study:  Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer PatientsStatus: Recruiting
Status: Recruiting
Sponsor: Oncology Specialists, S.C., Wyeth
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
Study:  Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg (CAMON)
Status: Recruiting
Sponsor: AstraZeneca
ClinicalTrials.gov Link: Click Here
June 9, 2009
Prostate Cancer Clinical Trial Announcement
Study:Â Â Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-Resistant Prostate Cancer
Status: Recruiting
Sponsor: Weill Medical College of Cornell University
ClinicalTrials.gov Link: Click Here
June 8, 2009
Prostate Cancer Clinical Trial Announcement
Study:Â Â Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)Status: Recruiting
Status: Not yet recruiting*
Anticipated start of recruitment: Unknown
Sponsor: Sanofi-Aventis
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
June 5, 2009
Prostate Cancer Clinical Trial Announcement
Study:Â Â Hypothermic Nerve Sparing Radical Prostatectomy
Status: Recruiting (by invitation)
Sponsor: University of California, Irvine
ClinicalTrials.gov Link: Click Here
June 2, 2009
Industry News
Medivation announces positive new efficacy data from Phase 1-2 trial of MDV3100 in advanced prostate cancer patients
June 1, 2009
Prostate Cancer Clinical Trial Announcement
Study:Â Â Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
Status: Recruiting
Sponsor: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
Study:Â Â QT/QTc and Multi-Dose Pharmacokinetic (PK) Study of Abiraterone Acetate
Status: Recruiting
Sponsor: Cougar Biotechnology
ClinicalTrials.gov Link: Click Here
Industry News
Ascenta Therapeutics announces presentation of promising results from clinical trials of AT-101 in prostate, brain, and lung cancers at 2009 ASCO annual meeting
Industry News
AEtna Zentaris presents data supporting evaluation of AEZS-108 in prostate cancer at ASCO meeting
Industry News
PROSTVAC data presented at ASCO meeting demonstrates the potential for significant increases in life expectancy in late-state prostate cancer
May 30, 2009
Industry News
OncoGenex Pharmaceuticals announces OGX-011 treatment provides survival benefit in randomized Phase 2 trial in advanced metastatic prostate cancer
May 28, 2009
Industry News
May 26, 2009
Prostate Cancer Clinical Trial Announcement
Study:Â Â GM-CSF in Treating Patients With Relapsed Prostate Cancer
Status: Not yet recruiting*
Anticipated start of recruitment: Unknown
Sponsor: The Cleveland Clinic, National Cancer Institute (NCI)
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
Prostate Cancer Clinical Trial Announcement
Study:Â Â Vaccine Therapy in Treating Patients With Progressive Stage D0 Prostate Cancer
Status: Recruiting
Sponsor: National Cancer Institute (NCI)
ClinicalTrials.gov Link: Click Here
May 22, 2009
Prostate Cancer Clinical Trial Announcement
Study:  RNActive®-Derived Therapeutic Vaccine
Status: Recruiting
Sponsor: University of Florida, CureVac GmbH
ClinicalTrials.gov Link: Click Here
May 7, 2009
Prostate Cancer Clinical Trial Announcement
Study: Â Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC)
Status: Not yet recruiting*
Anticipated start of recruitment: August 2009
Sponsor: Dendreon
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
May 6, 2009
Advocacy/Support
Team ZERO to Run to End Prostate Cancer in 2009 ING New York City Marathon:
May 5, 2009
CTAG News
Clinical Trials Advocacy Group for Prostate Cancer partners with “Prostate Cancer InfoLink”
Prostate Cancer InfoLink “offering the most user-friendly personalized prostate cancer information on the web” has agreed to feature CTAG for Prostate Cancer as its default search tool for prostate cancer clinical trials.
To view the Prostate Cancer InfoLink webpage Click Here
April 28, 2009
Industry News
OncoGenex receives confirmation from FDA on the design of a second Phase 3 trial evaluating OGX-011 for the treatment of advanced prostate cancer:
Industry News
Data presented at AUA demonstrate PROVENGE significantly prolongs survival for men with advanced prostate cancer in pivotal Phase 3 IMPACT study:
April 27, 2009
Industry News
Ferring Pharmaceuticals launches Phase IIIB trial of Degarelix as intermittent therapy:
April 24, 2009
Prostate Cancer Clinical Trial Announcement
Study: Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy
Status: Not yet recruiting*
Anticipated start of recruitment: March 2009
Sponsor: Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
April 23, 2009
Prostate Cancer Clinical Trial Announcement
Study: Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Status: Not yet recruiting*
Anticipated start of recruitment: July 2009
Sponsor: Duke University
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
Prostate Cancer Clinical Trial Announcement
Study: A Two-Dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy
 Status: Not yet recruiting*
 Anticipated start of recruitment: Unknown
 Sponsor: Johns Hopkins University
 ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment.  To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
April 18, 2009
Prostate Cancer Clinical Trial Announcement
Study: Abiraterone Acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer
Status: Not yet recruiting*
Anticipated start or recruitment: April 2009
Sponsor: Cougar Biotechnology
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
April 17, 2009
Prostate Cancer Clinical Trial Announcement
Study: Investigation of the effect of Degarelix in terms of prostate volume reduction in prostate cancer patients
Status: Not yet recruiting*
Anticipated start of recruitment: May 2009
Sponsor: Ferring Pharmaceuticals
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
March 31, 2009
Industry News
Stanford study on CyberKnife Radiosurgery for prostate cancer demonstrates 100 percent PSA response at 33 months:


